近5成中国成人受失眠困扰，DORA新药能否引领百亿赛道？

Core Insights - Sleep disorders have become a significant health issue affecting nearly half of the adult population in China, with a sleep disturbance rate of 48.5% among individuals aged 18 and above [1][2] - The average sleep duration for this demographic is between 7.06 to 7.18 hours, with women experiencing higher rates of sleep disturbances (51.1%) compared to men (45.9%) [1] - The prevalence of sleep disturbances increases with age, peaking at 73.7% among those aged 65 and above [1] Group 1: Health Implications - Insomnia is linked to various physical and mental health issues, including hypertension, diabetes, coronary heart disease, and cancer [1] - It also contributes to increased anxiety and a higher risk of suicide, as well as a rise in traffic accidents and decreased work efficiency, leading to greater socioeconomic burdens [1][2] Group 2: Treatment and Interventions - Multiple intervention methods for insomnia include lifestyle adjustments, psychological therapy, and pharmacological treatments, with a focus on cognitive behavioral therapy (CBT-I) as a primary approach [3][4] - New drug developments, particularly DORA (Dual Orexin Receptor Antagonists), aim to improve sleep quality without the side effects associated with traditional insomnia medications [5][6] Group 3: Market Potential - The sleep economy in China is projected to reach a market size of 534.93 billion yuan in 2024, with expectations to grow to 658.68 billion yuan by 2027, indicating strong growth potential [4] - The insomnia medication market was valued at 12.28 billion yuan in 2021, with forecasts of reaching 15.12 billion yuan by 2025 and 21.19 billion yuan by 2030 [5] Group 4: Regulatory and Accessibility Aspects - Recently approved DORA medications, such as Lemborexant and Daridorexant, have been included in the preliminary review list for the national medical insurance directory, enhancing their market accessibility [6] - These medications are not classified as controlled substances, which increases patient access and allows for innovative distribution channels, including e-commerce [6][7]